巴曲酶治疗糖尿病合并急性脑梗死的临床观察

目的 观察静脉注射巴曲酶治疗糖尿病合并脑梗死的有效性和安全性.方法 对66例糖尿病合并脑梗死患者采用静脉注射巴曲酶治疗;于治疗前、治疗后3 d和6 d进行神经功能缺损评分，同时进行凝血功能、血小板计数等实验室检查.结果 66例患者治疗后血浆纤维蛋白原浓度显著降低（ P〈0.001），神经功能缺损评分显著改善（ P〈0.001），总有效率为93.9%;未见药物不良反应.结论 早期巴曲酶静脉滴注可作为糖尿病合并急性脑梗死早期溶栓治疗的方法之一.

Clinical observation of Batroxobin on the diabetics complicated with acute cerebral infarction

ObjectiveTo observe the effect and security of Batroxobin vein injection on patients with diabetes mellitus and acute cerebral infarction.Methods66 patients with diabetes mellitus and acute cerebral infarction were treated with Batroxobin vein injection and assessed with the scale of neurological deficit before treatment and at 3rd and 6th day after treatment.At the same time the coagulant function and the count of blood platelet were measured.ResultsAfter treatment,the concentration of fibrinogen in blood plasma of patients decreased and scores of neurological deficit assessment improved both significantly(P<0.001).The total validity of Batroxobin vein injection was 93.9%.No side actions of drug were found.ConclusionBatroxobin vein injection can be used as a therapeutic method of dissolving thrombus in patients with diabetes mellitus and acute cerebral infarction in early stage.